ImmunityBio recently reported positive clinical data from its ANKTIVA (nogapendekin alfa inbakicept) program in non-small ...
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...
Company preparing to initiate first-in-human Phase 1 study of CRMA-1001 in early 2026 nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the ...
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...
The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...
All five patients in a trial with recurrent glioblastoma given a combination of ImmunityBio's (NASDAQ:IBRX) natural killer (NK) cell therapy Anktiva and Novocure's (NASDAQ:NVCR) Optune Gio Tumor ...
Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new drug candidates to send into human ...
Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.
Atopia Therapeutics SA has reported new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results